MedTrace Logo

Pharmacokinetic Study of Single and Multiple Intravenous Administration of Nalbuphine Hydrochloride Injection in Healthy Chinese Volunteers

NCT06902103 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2025-03-30

No results posted yet for this study

Summary

Objective：To evaluate the pharmacokinetic characteristics and safety of single and multiple intravenous injections of nalbuphine hydrochloride injection in healthy subjects.

Conditions

Interventions

DRUG

Nabufine Hydrochloride Injection

PartA: Nabufine Hydrochloride Injection are administered Intravenous injection single dose

DRUG

Nabufine Hydrochloride Injection

PartB: Nabufine Hydrochloride Injection are administered Intravenous injection multi dose

Sponsors & Collaborators

  • Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical Co. Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-12-20
Primary Completion
2023-12-26
Completion
2024-01-18

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06902103 on ClinicalTrials.gov